Abstract
Background
Primary hyperparathyroidism (HPT) is often caused by a benign parathyroid tumor, adenoma; less commonly by multiglandular parathyroid disease/hyperplasia; and rarely by parathyroid carcinoma. Patients with multiple tumors require wider exploration to avoid recurrence and have increased risk for hereditary disease. Secondary HPT is a common complication of renal failure. Improved knowledge of the molecular background of parathyroid tumor development may help select patients for appropriate surgical treatment and can eventually provide new means of treatment. The present contribution summarizes more recent knowledge of parathyroid molecular genetics.
Methods
A literature search and review was made to evaluate the level of evidence concerning molecular biology and genetics of primary, secondary, and familial HPT according to criteria proposed by Sackett, with recommendation grading by Heinrich et al.
Results
Most parathyroid adenomas and hyperplastic glands are monoclonal lesions. Cyclin D1 gene (CCND1) translocation and oncogene action occur in 8% of adenomas; cyclin D1 overexpression is seen in 20% to 40% of parathyroid adenomas and in 31% of secondary hyperplastic glands. Somatic loss of one MEN1 allele is seen in 25% to 40% of sporadic parathyroid adenomas, half of which have inactivating mutation of the remaining allele. Inactivating somatic HRPT2 mutations are common in parathyroid carcinoma, often causing decreased expression of the protein parafibromin involved in cyclin D1 regulation. Aberrant regulation of Wnt/β-catenin signaling may be important for parathyroid tumor development.
Conclusions
Molecular genetic studies of parathyroid tumors are well designed basic experimental studies providing strong level III evidence, with data frequently confirmed by subsequent studies.
Similar content being viewed by others
References
Lundgren E, Rastad J, Thurfjell E et al (1997) Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 294:287–294
Åkerström G, Rudberg C, Grimelius L et al (1986) Histologic parathyroid abnormalities in an autopsy series. Hum Pathol 7:520–527
Tisell LE, Carlsson S, Fjalling M et al (1985) Hyperparathyroidism subsequent to neck irradiation: risk factors. Cancer 56:1529–1533
Yoshimoto K, Yamasaki R, Sakai H et al (1989) Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab 68:976–981
Nussbaum SR, Gaz RD, Arnold A (1990) Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med 323:1324–1328
Strewler GJ, Budayr AA, Clark OH, Nissenson A (1993) Production of parathyroid hormone by a malignant nonparathyroid tumour in a hypercalcemic patient. J Clin Endocrinol Metab 76:1373–1375
St Goar WT (1963) Case records of the Massachusetts General Hospital. N Engl J Med 268:943–953
Smith JF (1970) Parathyroid adenomas associated with the malabsorption syndrome and chronic renal disease. J Clin Pathol 23:362–369
Rastad J, Åkerström G (1994) Secondary hyperparathyroidism. In: Åkerström G, Juhlin C, Rastad J (eds) Current controversy in parathyroid operation and reoperation. Landes, Austin
McIntosh WB, Horn EH, Mathieson LM et al (1987) The prevalence, mechanism and clinical significance of lithium-induced hypercalcaemia. Med Lab Sci 44:115–118
Toffaletti J, McComb RB, Bowers GN (1979) Increase in dialyzable calcium associated with therapy with lithium. Clin Chem 25:1806–1809
Sackett DL (1989) Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 95(Suppl 2):2s–4s
Heinrich S, Schafer M, Rousson V, Clavien PA (2006) Evidence-based treatment of acute pancreatitis: a look at established paradigms. Ann Surg 243:154–168
Fialkow PJ, Jackson CE, Block MA, Greenwald KA (1977) Multicellular origin of parathyroid “adenomas”. N Engl J Med 277:696–698
Arnold A, Staunton CE, Kim HG et al (1988) Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. N Engl J Med 318:658–662
Friedman E, Sakaguchi K, Bale AE et al (1989) Clonality of parathyroid tumours in familial multiple endocrine neoplasia type 1. N Engl J Med 32:213–218
Arnold A, Brown MF, Ureña P et al (1995) Monoclonality of parathyroid tumours in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 95:2047–2053
Tominaga Y, Kohara S, Namii Y et al (1996) Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg 20:744–750
Arnold A (1993) Genetic basis of endocrine disease. 5. Molecular genetics of parathyroid gland neoplasia. J Clin Endocrinol Metab 77:1108–1112
Åkerström G (1997) Non-familial primary hyperparathyroidism. Semin Surg Oncol 13:104–113
Wallfelt C, Gylfe E, Larsson R et al (1988) Relationship between external and cytoplasmic calcium concentrations, parathyroid hormone release and weight of parathyroid glands in human hyperparathyroidism. J Endocrinol 16:457–464
Nygren P, Larsson R, Johansson H et al (1988) Inhibition of cell growth retains the differentiated function of bovine parathyroid cells in monolayer culture. Bone Miner 4:123–132
LeBoff MS, Shoback D, Brown EM et al (1985) Regulation of parathyroid hormone release and cytosolic calcium by extracellular calcium in dispersed and cultured bovine and pathological human parathyroid cells. J Clin Invest 75:49–57
Wallfelt CH, Larsson R, Gylfe E et al (1988) Secretory disturbance in hyperplastic parathyroid nodules of uremic hyperparathyroidism: implication for parathyroid autotransplantation. World J Surg 12:431–438
Mun HC, Conigrave A, Wilkinson M, Delbridge L (2005) Surgery for hyperparathyroidism: does morphology or function matter most? Surgery 138:1111–1120
Brown EM (2007) Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab 3:122–133
Tfelt-Hansen J, Brown EM (2005) The calcium-sensing receptor in normal physiology and pathophysiology: a review. Clin Rev Clin Lab Sci 42:35–70
Arnold A, Kim HG, Gaz RD et al (1989) Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 83:2034–2040
Motokura T, Bloom T, Kim HG et al (1991) A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 350:512–515
Yi Y, Nowak NJ, Pacchia AL, Morrison C (2008) Chromosome 11 genomic changes in parathyroid adenoma and hyperplasia: array CGH, FISH, and tissue microarrays. Genes Chromosomes Cancer 47:639–648
Hsi ED, Zukerberg LR, Yang WI, Arnold A (1996) Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab 81:1736–1739
Tominaga Y, Tsuzuki T, Uchida K et al (1999) Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int 55:1375–1383
Vasef MA, Brynes RK, Sturm M et al (1999) Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol 12:412–416
Carpten JD, Robbins CM, Villablanca A et al (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumour syndrome. Nat Genet 32:676–680
Woodard GE, Lin L, Zhang JH et al (2005) Parafibromin, product of the hyperparathyroidism-jaw tumour syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 24:1272–1276
Mallya SM, Gallagher JJ, Wild YK et al (2005) Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism. Mol Endocrinol 19:2603–2609
Imanishi Y, Hosokawa Y, Yoshimoto K et al (2001) Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest 107:1093–1102
Farnebo F, Enberg U, Grimelius L et al (1997) Tumour-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism. J Clin Endocrinol Metab 82:3481–3486
Gogusev J, Duchambon P, Hory B et al (1997) Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 51:328–336
Cetani F, Picone A, Cerrai P et al (2000) Parathyroid expression of calcium-sensing receptor protein and in vivo parathyroid hormone-Ca(2+) set-point in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 85:4789–4794
Corbetta S, Mantovani G, Lania A et al (2000) Calcium-sensing receptor expression and signalling in human parathyroid adenomas and primary hyperplasia. Clin Endocrinol (Oxf) 52:339–348
Waller S, Kurzawinski T, Spitz L et al (2004) Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy. Eur J Pediatr 163:589–594
Fukumoto S, Chikatsu N, Okazaki R et al (2001) Inactivating mutations of calcium-sensing receptor results in parathyroid lipohyperplasia. Diagn Mol Pathol 10:242–247
Egbuna OI, Brown EM (2008) Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract Res Clin Rheumatol 22:129–148
Carling T, Szabo E, Bai M et al (2000) Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab 85:2042–2047
Szabo E, Carling T, Hessman O et al (2002) Loss of heterozygosity in parathyroid glands of familial hypercalcemia with hypercalciuria and point mutation in calcium receptor. J Clin Endocrinol Metab 87:3961–3965
Hosokawa Y, Pollak MR, Brown EM, Arnold A (1995) Mutational analysis of the extracellular Ca(2+)-sensing receptor gene in human parathyroid tumours. J Clin Endocrinol Metab 80:3107–3110
Degenhardt S, Toell A, Weidemann W et al (1998) Point mutations of the human parathyroid calcium receptor gene are not responsible for non-suppressible renal hyperparathyroidism. Kidney Int 53:556–561
Cetani F, Pinchera A, Pardi E et al (1999) No evidence for mutations in the calcium-sensing receptor gene in sporadic parathyroid adenomas. J Bone Miner Res 14:878–882
Nemeth EF, Steffey ME, Hammerland LG et al (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95:4040–4045
Trivedi R, Mithal A, Chattopadhyay N (2008) Recent updates on the calcium-sensing receptor as a drug target. Curr Med Chem 15:178–186
Chertow GM, Pupim LB, Block GA et al (2007) Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2:898–905
Günther T, Chen ZF, Kim J et al (2000) Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature 406:199–203
Canaff L, Zhou X, Mosesova I et al (2009) Glial cells missing-2 (GCM2) transactivates the calcium-sensing receptor gene: effect of a dominant-negative GCM2 mutant associated with autosomal dominant hypoparathyroidism. Hum Mutat 30:85–92
Correa P, Akerström G, Westin G (2002) Underexpression of Gcm2, a master regulatory gene of parathyroid gland development, in adenomas of primary hyperparathyroidism. Clin Endocrinol (Oxf) 57:501–505
Kebebew E, Peng M, Wong MG et al (2004) GCMB gene, a master regulator of parathyroid gland development, expression, and regulation in hyperparathyroidism. Surgery 136:1261–1266
Carling T, Kindmark A, Hellman P et al (1995) Vitamin D receptor genotypes in primary hyperparathyroidism. Nat Med 12:1309–1311
Carling T, Rastad J, Akerstrom G, Westin G (1998) Vitamin D receptor (VDR) and parathyroid hormone messenger ribonucleic acid levels correspond to polymorphic VDR alleles in human parathyroid tumors. J Clin Endocrinol Metab 83:2255–2259
Samander EH, Arnold A (2006) Mutational analysis of the vitamin D receptor does not support its candidacy as a tumour suppressor gene in parathyroid adenomas. J Clin Endocrinol Metab 91:5019–5021
Carling T, Rastad J, Szabó E et al (2000) Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. J Clin Endocrinol Metab 85:2000–2003
Sudhaker Rao D, Han ZH, Phillips ER et al (2000) Reduced vitamin D receptor expression in parathyroid adenomas: implications for pathogenesis. Clin Endocrinol (Oxf) 53:373–381
Correa P, Akerstrom G, Westin G (2002) Exclusive underexpression of vitamin D receptor exon 1f transcripts in tumors of primary hyperparathyroidism. Eur J Endocrinol 147:671–675
Segersten U, Correa P, Hewison M et al (2002) 25-Hydroxyvitamin D3-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab 87:2967–2972
Correa P, Segersten U, Hellman P et al (2002) Increased 25-hydroxyvitamin D3 1alpha-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors: new prospects for treatment of hyperparathyroidism with vitamin D. J Clin Endocrinol Metab 87:5826–5829
Segersten U, Björklund P, Hellman P et al (2007) Potentiating effects of nonactive/active vitamin D analogues and ketoconazole in parathyroid cells. Clin Endocrinol (Oxf) 66:399–404
Kilav R, Silver J, Naveh-Many T (2001) A conserved cis-acting element in the parathyroid hormone 3′-untranslated region is sufficient for regulation of RNA stability by calcium and phosphate. J Biol Chem 276:8727–8733
Costa-Guda J, Lauter K, Naveh-Many T et al (2006) Mutational analysis of the PTH 3′-untranslated region in parathyroid disorders. Clin Endocrinol (Oxf) 65:806–809
Chandrasekharappa SC, Guru SC, Manickam P et al (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276:404–407
Lemmens I, Van de Ven WJ, Kas K, Zhang CX et al (1997) Identification of the multiple endocrine neoplasia type 1 (MEN1) gene: the European Consortium on MEN1. Hum Mol Genet 6:1177–1183
Marx SJ (2005) Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 5:367–375
Heppner C, Kester MB, Agarwal SK et al (1997) Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet 16:375–378
Carling T, Correa P, Hessman O et al (1998) Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. J Clin Endocrinol Metab 83:2960–2963
Farnebo F, Teh BT, Kytölä S et al (1998) Alterations of the MEN1 gene in sporadic parathyroid tumours. J Clin Endocrinol Metab 83:2627–2630
Karges W, Jostarndt K, Maier S et al (2000) Multiple endocrine neoplasia type 1 (MEN1) gene mutations in a subset of patients with sporadic and familial primary hyperparathyroidism target the coding sequence but spare the promoter region. J Endocrinol 166:1–9
Miedlich S, Krohn K, Lamesch P et al (2000) Frequency of somatic MEN1 gene mutations in monoclonal parathyroid tumours of patients with primary hyperparathyroidism. Eur J Endocrinol 143:47–54
Uchino S, Noguchi S, Sato M et al (2000) Screening of the MEN1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumours. Cancer Res 60:5553–5557
Cetani F, Pardi E, Vignali E et al (2002) MEN1 gene alterations do not correlate with the phenotype of sporadic primary hyperparathyroidism. J Endocrinol Invest 25:508–512
Correa P, Juhlin C, Rastad J et al (2002) Allelic loss in clinically and screening-detected primary hyperparathyroidism. Clin Endocrinol (Oxf) 56:113–117
Tanaka C, Uchino S, Noguchi S et al (2002) Biallelic inactivation by somatic mutations of the MEN1 gene in sporadic parathyroid tumours. Cancer Lett 175:175–179
Falchetti A, Bale AE, Amorosi A et al (1993) Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11. J Clin Endocrinol Metab 76:139–144
Farnebo F, Farnebo LO, Nordenström J, Larsson C (1997) Allelic loss on chromosome 11 is uncommon in parathyroid glands of patients with hypercalcaemic secondary hyperparathyroidism. Eur J Surg 163:331–337
Tahara H, Imanishi Y, Yamada T et al (2000) Rare somatic inactivation of the multiple endocrine neoplasia type 1 gene in secondary hyperparathyroidism of uremia. J Clin Endocrinol Metab 85:4113–4117
Forsberg L, Villablanca A, Välimäki S et al (2001) Homozygous inactivation of the MEN1 gene as a specific somatic event in a case of secondary hyperparathyroidism. Eur J Endocrinol 145:415–420
Libutti SK, Crabtree JS, Lorang D et al (2003) Parathyroid gland-specific deletion of the mouse MEN1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Res 63:8022–8028
Lemos MC, Thakker RV (2008) Multiple endocrine neoplasia type 1 (MEN 1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 29:22–32
Balogh K, Rácz K, Patócs A, Hunyady L (2006) Menin and its interacting proteins: elucidation of menin function. Trends Endocrinol Metab 17:357–364
Dreijerink KM, Höppener JW, Timmers HM, Lips CJ (2006) Mechanisms of disease: multiple endocrine neoplasia type 1: relation to chromatin modifications and transcription regulation. Nat Clin Pract Endocrinol Metab 2:562–570
Agarwal SK, Guru SC, Heppner C et al (1999) Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96:143–152
Gobl AE, Berg M, Lopez-Egido JR et al (1999) Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism. Biochim Biophys Acta 1447:51–56
Agarwal SK, Novotny EA, Crabtree JS et al (2003) Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc Natl Acad Sci USA 100:10770–10775
Kim H, Lee JE, Cho EJ et al (2003) Menin, a tumour suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res 63:6135–6139
Kaji H, Canaff L, Lebrun JJ et al (2001) Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signalling. Proc Natl Acad Sci USA 98:3837–3842
Shattuck TM, Costa J, Bernstein M et al (2002) Mutational analysis of Smad3, a candidate tumour suppressor implicated in TGF-beta and menin pathways, in parathyroid adenomas and enteropancreatic endocrine tumours. J Clin Endocrinol Metab 87:3911–3914
Heppner C, Bilimoria KY, Agarwal SK et al (2001) The tumour suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 20:4917–4925
Corbetta S, Vicentini L, Ferrero S et al (2005) Activity and function of the nuclear factor kappaB pathway in human parathyroid tumours. Endocr Relat Cancer 12:929–937
Hughes CM, Rozenblatt-Rosen O, Milne TA et al (2004) Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell 13:587–597
Milne TA, Hughes CM, Lloyd R et al (2005) Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci USA 102:749–754
Karnik SK, Hughes CM, Gu X et al (2005) Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci USA 102:14659–14664
Buchwald PC, Akerström G, Westin G (2004) Reduced p18INK4c, p21CIP1/WAF1 and p27KIP1 mRNA levels in tumours of primary and secondary hyperparathyroidism. Clin Endocrinol (Oxf) 60:389–393
Lindberg D, Åkerström G, Westin G (2008) Evaluation of CDKN2C/p18, CDKN1B/p27 and CDKN2B/p15 mRNA expression, and CpG methylation status in sporadic and MEN1-associated pancreatic endocrine tumours. Clin Endocrinol (Oxf) 68:271–277
Lindberg D, Åkerström G, Westin G (2007) Mutational analysis of p27 (CDKN1B) and p18 (CDKN2C) in sporadic pancreatic endocrine tumours argues against tumour-suppressor function. Neoplasia 9:533–535
Lauter KB, Arnold A (2008) Mutational analysis of CDKN1B, a candidate tumour-suppressor gene, in refractory secondary/tertiary hyperparathyroidism. Kidney Int 73:1137–1140
Yokoyama A, Somervaille TC, Smith KS et al (2005) The menin tumour suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123:207–218
Shen HC, Rosen JE, Yang LM et al (2008) Parathyroid tumour development involves deregulation of homeobox genes. Endocr Relat Cancer 15:267–275
Willeke F, Hauer MP, Buchcik R et al (1998) Multiple endocrine neoplasia type 2-associated RET proto-oncogene mutations do not contribute to the pathogenesis of sporadic parathyroid tumours. Surgery 124:484–490
Polakis P (2007) The many ways of Wnt in cancer. Curr Opin Genet Dev 17:45–51
Björklund P, Åkerström G, Westin G (2007) Accumulation of nonphosphorylated β-catenin and c-myc in primary and uremic secondary hyperparathyroid tumours. J Clin Endocrinol Metab 92:338–344
Björklund P, Lindberg D, Åkerström G, Westin G (2008) Stabilizing mutation of CTNNB1/β-catenin in a large series of parathyroid tumours of Swedish patients. Mol Cancer 7:53
Costa-Guda J, Arnold A (2007) Absence of stabilizing mutations of beta-catenin encoded by CTNNB1 exon 3 in a large series of sporadic parathyroid adenomas. J Clin Endocrinol Metab 92:1564–1566
Björklund P, Åkerström G, Westin G (2007) A LPR5 receptor with internal deletion in hyperparathyroid tumours with implications for deregulated Wnt/β-catenin signalling. PLoS Med 4:e328
Björklund P, Åkerström G, Westin G (2007) Activated beta-catenin in the novel human parathyroid tumour cell line sHPT-1. Biochem Biophys Res Commun 352:532–536
Rozenblatt-Rosen O, Hughes CM, Nannnepaga SJ et al (2005) The parafibromin tumour suppressor protein is part of a human Paf1 complex. Mol Cell Biol 25:612–620
Tan MH, Morrison C, Wang P et al (2004) Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 10:6629–6637
Dwight T, Nelson AE, Theodosopoulos G et al (2002) Independent genetic events associated with the development of multiple parathyroid tumors in patients with primary hyperparathyroidism. Am J Pathol 161:1299–1306
Åkerström G, Hellman P (2003) Primary hyperparathyroidism. Curr Opin Oncol 16:1–7
Farnebo F, Teh BT, Dotzenrath C et al (1997) Differential loss of heterozygosity in familial, sporadic, and uremic hyperparathyroidism. Hum Genet 99:342–349
Chudek J, Ritz E, Kovacs G (1998) Genetic abnormalities in parathyroid nodules of uremic patients. Clin Cancer Res 4:211–214
Nagy A, Chudek J, Kovacs G (2001) Accumulation of allelic changes at chromosomes 7p, 18q, and 2 in parathyroid lesions of uremic patients. Lab Invest 81:527–533
Imanishi Y, Tahara H, Palanisamy N et al (2002) Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. J Am Soc Nephrol 13:1490–1498
Farnebo F, Kytola S, Teh BT et al (1999) Alternative genetic pathways in parathyroid tumourigenesis. J Clin Endocrinol Metab 84:3775–3780
Haven CJ, Howell VM, Eilers PH et al (2004) Gene expression of parathyroid tumours: molecular subclassification and identification of the potential malignant phenotype. Cancer Res 64:7405–7411
Morrison C, Farrar W, Kneile J et al (2004) Molecular classification of parathyroid neoplasia by gene expression profiling. Am J Pathol 165:565–576
Forsberg L, Björck E, Hashemi J et al (2005) Distinction in gene expression profiles demonstrated in parathyroid adenomas by high-density oligoarray technology. Eur J Endocrinol 152:459–470
Rosen JE, Costouros NG, Lorang D et al (2005) Gland size is associated with changes in gene expression profiles in sporadic parathyroid adenomas. Ann Surg Oncol 12:412–416
Velázquez-Fernández D, Laurell C, Saqui-Salces M et al (2006) Differential RNA expression profile by cDNA microarray in sporadic primary hyperparathyroidism (pHPT): primary parathyroid hyperplasia versus adenoma. World J Surg 30:705–713
Schachter PP, Ayesh S, Matouk I et al (2007) Differential expression of kinase genes in primary hyperparathyroidism: adenoma versus normal and hyperplastic parathyroid tissue. Arch Pathol Lab Med 131:126–130
Kuro-o M, Matsumura Y, Aizawa H et al (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45–51
Sugiura H, Yoshida T, Tsuchiya K et al (2005) Klotho reduces apoptosis in experimental ischaemic acute renal failure. Nephrol Dial Transplant 20:2636–2645
Ikushima M, Rakugi H, Ishikawa K et al (2006) Anti-apoptotic and anti-senescence effects of Klotho on vascular endothelial cells. Biochem Biophys Res Commun 339:827–832
Medici D, Razzaque MS, Deluca S et al (2008) FGF-23-Klotho signalling stimulates proliferation and prevents vitamin D-induced apoptosis. J Cell Biol 182:459–465
Imura A, Tsuji Y, Murata M et al (2007) α-Klotho as a regulator of calcium homeostasis. Science 316:1615–1618
Chang Q, Hoefs S, van der Kemp AW et al (2005) The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 310:490–493
Lu P, Boros S, Chang Q et al (2008) The beta-glucuronidase klotho exclusively activates the epithelial Ca2+ channels TRPV5 and TRPV6. Nephrol Dial Transplant 11:3397–3402
Lu L, Katsaros D, Wiley A et al (2008) Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression. Cancer Invest 26:185–192
Wolf I, Levanon-Cohen S, Bose S et al (2008) Klotho: a tumour suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 27:7094–7105
Liu H, Fergusson MM, Castilho RM et al (2007) Augmented Wnt signalling in a mammalian model of accelerated aging. Science 317:803–806
Kurosu H, Ogawa Y, Miyoshi M et al (2006) Regulation of fibroblast growth factor-23 signalling by klotho. J Biol Chem 281:6120–6123
Urakawa I, Yamazaki Y, Shimada T et al (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770–774
Goetz R, Beenken A, Ibrahimi OA et al (2007) Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 27:3417–3428
Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003–4008
Krajisnik T, Björklund P, Marsell R et al (2007) Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:125–131
Björklund P, Krajisnik T, Akerström G et al (2008) Type I membrane klotho expression is decreased and inversely correlated to serum calcium in primary hyperparathyroidism. J Clin Endocrinol Metab 93:4152–4157
Zhang H, Li Y, Fan Y et al (2008) Klotho is a target gene of PPAR-gamma. Kidney Int 74:732–739
Brownstein CA, Adler F, Nelson-Williams C et al (2008) A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci USA 105:3455–3460
Åkerström G, Hellman P, Björklund P (2008) Parathyroid carcinoma. In: Hay I, Wass JAH (eds) Clinical endocrinology, 2nd edn. Blackwell, Chichester
DeLellis RA (2005) Parathyroid carcinoma: an overview. Adv Anat Pathol 12:53–61
Haven CJ, van Puijenbrock M, Karperien M et al (2004) Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma. J Pathol 202:86–94
Fernandez-Ranvier GG, Khanafshar E, Tacha D et al (2009) Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer 115:334–444
Hunt JL, Carty SE, Yim IH et al (2005) Allelic loss in parathyroid neoplasia can help characterize malignancy. Am J Surg Pathol 29:1049–1055
Rogers SE, Perrier ND (2006) Parathyroid carcinoma. Curr Opin Oncol 18:16–22
Rawat N, Khetan N, Williams DW et al (2005) Parathyroid carcinoma. Br J Surg 92:1345–1353
Mittendorf EA, McHenry CR (2005) Parathyroid carcinoma. J Surg Oncol 89:136–142
Välimäki S, Forsberg L, Farnebo LO et al (2002) Distinct target regions for chromosome 1p deletions in parathyroid adenomas and carcinomas. Int J Oncol 21:727–735
Shattuck TM, Välimäki S, Obara T et al (2003) Somatic and germ-line mutations of the HRTP2 gene in sporadic parathyroid carcinoma. N Engl J Med 349:1722–1729
Howell VM, Haven CJ, Kahnoski K et al (2003) HRPT2 mutations are associated with malignancy in sporadic parathyroid tumors. J Med Genet 40:657–663
Gill AJ, Clarkson A, Gimm O et al (2006) Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30:1140–1149
Cetani F, Ambrogini E, Viacava P et al (2007) Should parafibromin staining replace HRPT2 gene analysis as an additional tool for histological diagnosis of parathyroid carcinoma? Eur J Endocrinol 156:547–554
Haven CJ, van Puijenbroek M, Tan MH et al (2007) Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol (Oxf) 67:370–376
Hewitt KM, Sharma PK, Samowitz W, Hobbs M (2007) Aberrant methylation of the HRPT2 gene in parathyroid carcinoma. Ann Otol Rhinol Laryngol 116:928–933
Juhlin CC, Villablanca A, Sandelin K et al (2007) Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer 14:501–512
Juhlin CC, Haglund F, Villablanca A et al (2009) Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-β in parathyroid carcinomas. Int J Oncol 34:481–492
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Westin, G., Björklund, P. & Åkerström, G. Molecular Genetics of Parathyroid Disease. World J Surg 33, 2224–2233 (2009). https://doi.org/10.1007/s00268-009-0022-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-009-0022-6